These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19130320)

  • 1. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
    Huang CT; Yen RF; Cheng MF; Hsu YC; Wei PF; Tsai YJ; Tsai MF; Shih JY; Yang CH; Yang PC
    Med Oncol; 2010 Mar; 27(1):9-15. PubMed ID: 19130320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.
    Lee EY; Khong PL; Lee VH; Qian W; Yu X; Wong MP
    Clin Nucl Med; 2015 Mar; 40(3):e190-5. PubMed ID: 25608155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
    Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
    Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between EGFR mutation status and F
    Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W
    Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
    Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
    Ding CY; Yang WP; Guo Z; Sun J; Li YY; Li TR
    Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):528-531. PubMed ID: 28728300
    [No Abstract]   [Full Text] [Related]  

  • 7. [Value of (18)F-FDG PET-CT imaging to predict epidermal growth factor receptor mutations in patients with lung squamous cell carcinoma].
    Zhao CY; Deng XY; Wang HS; Cao GP; Ding JN; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):795-800. PubMed ID: 34289575
    [No Abstract]   [Full Text] [Related]  

  • 8. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
    Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K
    PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total lesion glycolysis determined per RECIST 1.1 criteria predicts survival in EGFR mutation-negative patients with advanced lung adenocarcinoma.
    Ho TY; Chou PC; Yang CT; Tsang NM; Yen TC
    Clin Nucl Med; 2015 Jun; 40(6):e295-9. PubMed ID: 25783515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma.
    Putora PM; Früh M; Müller J
    Respirology; 2013 May; 18(4):734-5. PubMed ID: 23489365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations.
    Wumener X; Zhang Y; Zang Z; Du F; Ye X; Zhang M; Liu M; Zhao J; Sun T; Liang Y
    BMC Pulm Med; 2024 May; 24(1):227. PubMed ID: 38730287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG PET texture indices as imaging biomarkers for epidermal growth factor receptor mutation status in lung adenocarcinoma.
    Ishimura M; Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Murota M; Kanaji N; Nishiyama Y
    Sci Rep; 2023 Apr; 13(1):6742. PubMed ID: 37185611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
    Wang D; Zhang M; Gao X; Yu L
    PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
    Takahashi R; Hirata H; Tachibana I; Shimosegawa E; Inoue A; Nagatomo I; Takeda Y; Kida H; Goya S; Kijima T; Yoshida M; Kumagai T; Kumanogoh A; Okumura M; Hatazawa J; Kawase I
    Clin Cancer Res; 2012 Jan; 18(1):220-8. PubMed ID: 22019513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of ¹⁸Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma.
    Kanmaz ZD; Aras G; Tuncay E; Bahadır A; Kocatürk C; Yaşar ZA; Öz B; Özkurt CÜ; Gündoğan C; Çermik TF
    Cancer Biomark; 2016; 16(3):489-98. PubMed ID: 27062706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of
    Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.
    Kaira K; Shimizu K; Kitahara S; Yajima T; Atsumi J; Kosaka T; Ohtaki Y; Higuchi T; Oyama T; Asao T; Mogi A
    Eur J Cancer; 2018 Sep; 101():181-190. PubMed ID: 30077123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in Lung Cancer.
    Park JS; Park HY; Choi Y
    Anticancer Res; 2024 Jun; 44(6):2681-2687. PubMed ID: 38821597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
    Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis.
    Na II; Byun BH; Kim KM; Cheon GJ; Choe du H; Koh JS; Lee DY; Ryoo BY; Baek H; Lim SM; Yang SH; Kim CH; Lee JC
    Lung Cancer; 2010 Jan; 67(1):76-80. PubMed ID: 19371962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.